ASX Health Stocks: Oneview extends software deal, LCT to start using AI technology

Oneview extends supply deal to BJC’s hospital beds
LCT will start to use artificial intelligence in its research
AFT Pharma’s solid FY22

Oneview extends hospital deal with BCJ Health

Healthcare software company Oneview Healthcare (ASX:ONE) has signed a deal with BJC Health System to provide Oneview’s platform to 2,441 additional beds.

The agreement represents a 20% increase under an existing contract with BCJ, which now takes the number of beds using Oneview’s platform to 14,283.

Under this agreement, BJC will also be migrating to Oneview’s CXP Cloud Enterprise platform, and moving all existing deployments to Android hardware.

BCJ and Oneview have been partners since 2016, and the companies extended the partnership in 2021 by conducting a series of joint workshops to assess how technology could support the traditional care model during a pandemic.

The Oneview platform is reported to be the world’s first and only cloud-based care experience platform. It provides patients with a digital tablet at their bedside that uses real time information intended to make a patient’s stay easier.

“The pandemic has raised the importance of bedside technology for enabling self-service, keeping patients, families and clinicians connected, and supporting hybrid care models,” said CEO of Oneview, James Fitter.

“BJC Health System has a clear and innovative vision for how technology can support inpatient care into the future with the ‘Connected Patient Room’, he added.

Oneview share price today:

Living Cell Technologies to use AI technology

Living Cell Technologies (ASX:LCT) is entering a new phase, with artificial intelligence to be applied to the company’s research to combat Parkinson’s disease.

LCT says the use of AI will ensure that the NTCELL product being manufactured for the company’s third clinical trial of NTCELL in Parkinson’s disease is of the highest possible quality.

Specifically, the company will evaluate strategies to ensure that the pig choroid plexus cells selected for encapsulation are of optimal quality.

“This is an exciting step in the manufacture of NTCELL,” said LCT executive chairman, Professor Bernie Tuch.

“It introduces modern technology to ensure that the product released for clinical use will be of the highest standard, improving the prospects of a successful result.”

LCT share price today:

AFT Pharma’s solid FY22

AFT Pharma’s (ASX:AFP) annual operating revenue for the full year of FY22 was up 15.2% to $130.3 million, while its net profit after tax was $19.8 million, up from $7.8 million in the previous year.

Australian sales were up 12.3%, while the company saw double digit growth across all channels despite Covid-19 restrictions.

Overseas, strong revenue growth was underpinned by the licensing of Maxigesic IV in the US to Hikma Pharmaceuticals.

Looking ahead, AFP says it continues to see considerable opportunities for growth, and has thus increased both its in-licensing and R&D pipeline activities.

On this basis, the company says it expects operating profit for the year to 31 March 2023 to range between $27 million and $32 million.